Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Long-Term Investments: 2020-2024

Historic Long-Term Investments for Kymera Therapeutics (KYMR) over the last 5 years, with Dec 2024 value amounting to $362.2 million.

  • Kymera Therapeutics' Long-Term Investments rose 31.04% to $473.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.1 million, marking a year-over-year increase of 31.04%. This contributed to the annual value of $362.2 million for FY2024, which is 489.58% up from last year.
  • As of FY2024, Kymera Therapeutics' Long-Term Investments stood at $362.2 million, which was up 489.58% from $61.4 million recorded in FY2023.
  • Kymera Therapeutics' Long-Term Investments' 5-year high stood at $362.2 million during FY2024, with a 5-year trough of $61.4 million in FY2023.
  • Its 3-year average for Long-Term Investments is $192.0 million, with a median of $152.3 million in 2022.
  • Per our database at Business Quant, Kymera Therapeutics' Long-Term Investments plummeted by 59.67% in 2023 and then skyrocketed by 489.58% in 2024.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Long-Term Investments stood at $162.5 million in 2020, then decreased by 22.97% to $125.2 million in 2021, then rose by 21.67% to $152.3 million in 2022, then tumbled by 59.67% to $61.4 million in 2023, then surged by 489.58% to $362.2 million in 2024.